BR112018015482A2 - derivado de imidazol, seu método de preparo e uso, composto, composição farmacêutica e método para tratar doenças - Google Patents

derivado de imidazol, seu método de preparo e uso, composto, composição farmacêutica e método para tratar doenças

Info

Publication number
BR112018015482A2
BR112018015482A2 BR112018015482-2A BR112018015482A BR112018015482A2 BR 112018015482 A2 BR112018015482 A2 BR 112018015482A2 BR 112018015482 A BR112018015482 A BR 112018015482A BR 112018015482 A2 BR112018015482 A2 BR 112018015482A2
Authority
BR
Brazil
Prior art keywords
imidazole
derived
compound
preparation
pharmaceutical composition
Prior art date
Application number
BR112018015482-2A
Other languages
English (en)
Korean (ko)
Inventor
Hah Jung-Mi
I Yang Song
Hun Lee Jung
Original Assignee
Samjin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samjin Pharmaceutical Co., Ltd. filed Critical Samjin Pharmaceutical Co., Ltd.
Publication of BR112018015482A2 publication Critical patent/BR112018015482A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção se refere a um derivado de imidazol inovador que tem uma atividade inibidora de quinase c-jun n-terminal (jnk) e um uso do mesmo. um derivado de imidazol inovador ou um sal farmaceuticamente aceitável do mesmo de acordo com a presente invenção exibe uma atividade inibidora excelente contra quinase c-jun n-terminal (jnk), e, desse modo, antecipa-se que uma abordagem mais fundamental e o tratamento-alvo serão possíveis na prevenção ou tratamento de doenças de sistema nervoso cerebral degenerativas.
BR112018015482-2A 2016-01-29 2017-01-25 derivado de imidazol, seu método de preparo e uso, composto, composição farmacêutica e método para tratar doenças BR112018015482A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0011683 2016-01-29
KR20160011683 2016-01-29
PCT/KR2017/000860 WO2017131425A1 (ko) 2016-01-29 2017-01-25 Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도

Publications (1)

Publication Number Publication Date
BR112018015482A2 true BR112018015482A2 (pt) 2018-12-18

Family

ID=59398384

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015482-2A BR112018015482A2 (pt) 2016-01-29 2017-01-25 derivado de imidazol, seu método de preparo e uso, composto, composição farmacêutica e método para tratar doenças

Country Status (11)

Country Link
US (1) US10301291B2 (pt)
EP (1) EP3409668B1 (pt)
JP (1) JP6626981B2 (pt)
KR (1) KR101894096B1 (pt)
CN (1) CN108699041B (pt)
BR (1) BR112018015482A2 (pt)
CA (1) CA3013022C (pt)
ES (1) ES2830743T3 (pt)
MX (1) MX2018009097A (pt)
RU (1) RU2702749C1 (pt)
WO (1) WO2017131425A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020022787A1 (ko) * 2018-07-24 2020-01-30 삼진제약주식회사 Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물
KR102514245B1 (ko) * 2019-12-03 2023-03-29 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 피라졸 유도체 및 이의 용도
KR102642716B1 (ko) * 2021-08-18 2024-03-04 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1297447A (zh) * 1998-02-17 2001-05-30 图拉列克股份有限公司 抗病毒嘧啶衍生物
KR100337189B1 (ko) 1999-09-30 2002-05-18 복성해 인간세포의 인산화 효소 ｊｎｋ의 활성 조절인자로 작용하는 마우스의 ｓｋｉｐ 단백질 및 ｓｋｉｐ 유전자
US6410726B1 (en) * 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
WO2003011836A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2401265C2 (ru) * 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
KR20070119690A (ko) * 2005-03-15 2007-12-20 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
KR101123071B1 (ko) * 2009-10-23 2012-03-05 한국과학기술연구원 신규 이미다졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 흑색종의 예방 및 치료용 약학적 조성물
KR101469127B1 (ko) * 2013-03-11 2014-12-04 한양대학교 에리카산학협력단 신규 벤즈이미다졸 유도체, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
EP3409668A1 (en) 2018-12-05
KR101894096B1 (ko) 2018-09-05
JP6626981B2 (ja) 2019-12-25
EP3409668B1 (en) 2020-10-21
CN108699041B (zh) 2021-03-26
ES2830743T3 (es) 2021-06-04
CN108699041A (zh) 2018-10-23
RU2702749C1 (ru) 2019-10-11
CA3013022C (en) 2020-09-22
MX2018009097A (es) 2019-03-06
CA3013022A1 (en) 2017-08-03
US20190031645A1 (en) 2019-01-31
US10301291B2 (en) 2019-05-28
KR20170091516A (ko) 2017-08-09
JP2019508396A (ja) 2019-03-28
EP3409668A4 (en) 2019-07-31
WO2017131425A1 (ko) 2017-08-03

Similar Documents

Publication Publication Date Title
PH12017500146A1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
BR112016005881A2 (pt) composto, composição farmacêutica e uso do composto
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
BR112017024933A2 (pt) alvocidib produce com a bioavailabilidade aumentada
BR112014029851A2 (pt) composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
BR112014019052A8 (pt) Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
MX2018011784A (es) Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
CR20190530A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112018007128A2 (pt) compostos para a inibição de câncer e epigênese
BR112018015482A2 (pt) derivado de imidazol, seu método de preparo e uso, composto, composição farmacêutica e método para tratar doenças
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112018076821A2 (pt) derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) [chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements